Patents by Inventor Florian Puhler
Florian Puhler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180042931Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) wherein LA represents *CH2** or *?**; wherein indicates the point of attachment to the carbonyl group, and ** indicates the point of attachment to R1; LB represents *N(H)—C(?O)** or *C(?O)—N(H)**; wherein * indicates the point of attachment to R2, and ** indicates the point of attachment to the phenyl group; R1 represents a group selected from: (AA); wherein * indicates the point of attachment to LA, R2 represents: (BB) wherein * indicates the point of attachment to R3, and ** indicates the point of attachment to LB R3 represents a group selected from: (CC); wherein * indicates the point of attachment to R2; R4 and R5 represent a hydrogen atom; and R6 represents a halogen atom or group selected from: —CH3, —O—CH3, —O—CHF2, —O—CF3, and —O-cyclopropyl; to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturingType: ApplicationFiled: February 16, 2016Publication date: February 15, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES
-
Publication number: 20180044306Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: February 16, 2016Publication date: February 15, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES, Jens GEISLER
-
Publication number: 20180028507Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients, in which: R1 represents a group selected from: C1-C3-alkoxy-C2-C3-alkyl-, (A), (B), (C), (D), (E), (F), (G) or (H); wherein * indicates the point of attachment to the rest of the molecule; R2 represents a group selected from: (I), (J) or (K); wherein * indicates the point of attachment to the rest of the molecule.Type: ApplicationFiled: February 16, 2016Publication date: February 1, 2018Applicant: Bayer Pharma AktiengesellschaftInventors: Kai THEDE, Eckhard BENDER, William J. SCOTT, Anja GIESE, Ludwig ZORN, Ningshu LIU, Ursula MÖNNING, Franziska SIEGEL, Stefan GOLZ, Andrea HÄGEBARTH, Philip LIENAU, Florian PÜHLER, Daniel BASTING, Dirk SCHNEIDER, Manfred MÖWES
-
Patent number: 9730929Abstract: The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 30, 2012Date of Patent: August 15, 2017Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
-
Patent number: 9556181Abstract: The present invention relates to substituted pyrazolopyrimidinylamino-indazole compounds of formula I, below, as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients wherein R1a, R1b, R1c, and R2 are defined herein.Type: GrantFiled: January 29, 2014Date of Patent: January 31, 2017Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Klar, Lars Wortmann, Georg Kettschau, Florian Pühler, Philip Lienau, Detlev Sülzle
-
Patent number: 9381177Abstract: The present invention relates to: combinations of: component A: one or more omega-carboxyaryl-substituted diphenyl urea compounds of general formula (I), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; component B: one or more N-(2-arylamino)aryl sulfonamide compounds of general formula (II), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; and, optionally, component C: one or more further pharmaceutical agents; in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially. dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route; use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; and a kit comprising such a combination.Type: GrantFiled: September 29, 2011Date of Patent: July 5, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Florian Pühler, Marion Hitchcock
-
Publication number: 20160159816Abstract: The present invention relates to substituted thienopyrimidine compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: January 29, 2014Publication date: June 9, 2016Applicant: Bayer Pharma AktiengesellschaftInventors: Georg KETTSCHAU, Florian PÜHLER, Ulrich KLAR, Lars WORTMANN, Philip LIENAU, Dirk KOSEMUND, Detlev SÜLZLE, Andrea HÄGEBARTH
-
Patent number: 9296757Abstract: The present invention relates to substituted benzothienopyrimidine compounds of general formula I: in which R1a, R1b, R2a, R2b, and R2c are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: May 17, 2013Date of Patent: March 29, 2016Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich Klar, Georg Kettschau, Dirk Kosemund, Florian Pühler, Knut Eis, Philip Lienau, Ulf Bömer, Detlev Sülzle, Lars Wortmann
-
Patent number: 9284319Abstract: The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: June 21, 2012Date of Patent: March 15, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
-
Publication number: 20160002245Abstract: The present invention relates to substituted pyrazolopyrimidinylamino-indazole compounds of general formula I as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: January 29, 2014Publication date: January 7, 2016Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ulrich KLAR, Lars WORTMANN, Georg KETTSCHAU, Florian PÜHLER, Philip LIENAU, Detlev SÜLZLE
-
Publication number: 20150267258Abstract: This invention is directed to the use of one or more biomarkers defined as KRAS or NRAS gene for predicting the pharmaceutical efficacy or clinical response of MEK protein kinase inhibitor and/or Sorafenib or Regorafenib to be administered to a Hepatocellular carcinoma (HCC) patient. Further the invention is directed to in-vitro methods for identifying mutated-type KRAS or NRAS gene in HCC patient and kits thereof.Type: ApplicationFiled: May 27, 2013Publication date: September 24, 2015Inventors: Heiko Krissel, Florian Pühler, Michael Jeffers
-
Publication number: 20150152121Abstract: The present invention relates to substituted benzothienopyrimidine compounds of general formula I: in which R1a, R1b, R2a, R2b, and R2c are as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 17, 2013Publication date: June 4, 2015Inventors: Ulrich Klar, Georg Kettschau, Dirk Kosemund, Florian Pühler, Knut Eis, Philip Lienau, Ulf Bömer, Detlev Sülzle, Lars Wortmann
-
Patent number: 8993630Abstract: The present invention relates to substituted sulphonamido phenoxybenzamide compounds of general formula (I): in which A, R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined in the claims, to pharmaceutical compositions and combinations containing said compounds, to methods of preparing said compounds, and to the use of said compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 28, 2009Date of Patent: March 31, 2015Assignee: Bayer Intellectual Property GmbHInventors: Ingo Hartung, Marion Hitchcock, Florian Puhler, Gerhard Siemeister, Roland Neuhaus
-
Patent number: 8962606Abstract: The present invention relates to substituted benzosulphonamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: GrantFiled: October 7, 2010Date of Patent: February 24, 2015Assignee: Bayer Intellectual Property GmbHInventors: Marion Hitchcock, Ingo Hartung, Florian Pühler
-
Publication number: 20150038485Abstract: The present invention relates to heterocyclyl aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: June 21, 2012Publication date: February 5, 2015Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
-
Publication number: 20140296231Abstract: The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I): in which A, R1, R3 and n are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: September 5, 2012Publication date: October 2, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Knut EIS, Florian PÜHLER, Ludwig ZORN, Arne SCHOLZ, Philip LIENAU, Mark Jean GNOTH, Ulf BÖMER, Judith GÜNTHER, Marion HITCHCOCK
-
Publication number: 20140288069Abstract: The present invention relates to amino imidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said 10 compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 14, 2012Publication date: September 25, 2014Applicant: Bayer Intellectual Property GmbHInventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
-
Publication number: 20140194430Abstract: The present invention relates to substituted aminoimidazopyridazine compounds of general formula (I): in which A, R1, R2, R3 and R4 are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: May 30, 2012Publication date: July 10, 2014Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Knut Eis, Florian Pühler, Ludwig Zorn, Arne Scholz, Philip Lienau, Mark Jean Gnoth, Ulf Bömer, Judith Günther, Jörg Fanghänel, Daniel Korr
-
Publication number: 20130261120Abstract: The present invention relates to: *combinations of: component A: one or more omega-carboxyaryl-substituted diphenyl urea compounds of general formula (I), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; component B: one or more N-(2-arylamino) aryl sulfonamide compounds of general formula (II), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; and, optionally, component C: one or more further pharmaceutical agents; in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially. dependently of one another by the oral, intravenous, topical, local installations, intraperitoneal or nasal route; *use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; and *a kit comprising such a combination.Type: ApplicationFiled: September 29, 2011Publication date: October 3, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Florian Pühler, Marion Hitchcock
-
Publication number: 20120269804Abstract: The present invention relates to substituted benzosulphonamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.Type: ApplicationFiled: October 7, 2010Publication date: October 25, 2012Applicant: Bayer Intellectual Property GmbHInventors: Marion Hitchcock, Ingo Hartung, Florian Pühler